The fixed-dose combination therapy Duodart is generally used for the long-term management of symptomatic Benign Prostatic Hyperplasia (BPH) in adult men. This medication is applied across therapeutic domains involving distressing lower urinary tract symptoms. These symptoms relate to organ-specific functional stress, including a weak urine stream, difficulty initiating urination, frequent urges, and nocturia. The medication is relevant in conditions characterized by periods of heightened symptoms.

The primary goal of the treatment is to help manage the symptomatic burden associated with an enlarged prostate. It is used for managing the obstructive symptoms—like flow restriction—and addressing irritative symptoms—such as frequency and urgency. The therapy contributes to improved comfort and helps maintain functional stability when symptoms interfere with routine activities, while also playing a role in reducing the risk of BPH-related clinical progression.

---

Quick Facts: Therapeutic Focus

Property	Description
Primary Indication	Symptomatic Benign Prostatic Hyperplasia (BPH)
Symptom Domains	Helps address symptom clusters related to flow and urgency
Clinical Scenario	Long-term symptomatic support for chronic conditions
Key Benefit	Supports easing the overall symptom load and risk management

The fixed-dose medicine Duodart (Dutasteride/Tamsulosin) is strictly limited to adult men (aged 18 and over). Use in older adults is considered established.

Absolute Contraindications

Regulatory documents state the medicine must not be used by women, including those who are or may become pregnant, or by any pediatric patients (under 18). It is also contraindicated in patients with certain conditions, including severe hepatic impairment (severe liver dysfunction), a history of orthostatic hypotension, or known hypersensitivity to the active ingredients or excipients like soya or peanut.

Conditional Restrictions

Caution is required for use in patients with mild-to-moderate hepatic impairment or severe renal impairment (creatinine clearance < 10 mL/min). The initiation of therapy is not recommended for patients scheduled for cataract surgery. Due to the risk of fetal exposure to dutasteride, women and children must avoid contact with leaking capsules, and eligible male patients must not donate blood for a period of six months after discontinuation.

Interactions with other medicines and products

Duodart (Dutasteride/Tamsulosin) has documented interactions that require caution or contraindication, primarily related to its metabolism and pharmacologic effects.

Contraindicated Combinations

Co-administration of Duodart is contraindicated with other alpha-adrenergic antagonists due to the potential for severe additive hypotensive effects. Additionally, strong inhibitors of the enzyme CYP3A4 (such as ketoconazole) are contraindicated because they can significantly increase the systemic exposure of the tamsulosin component, raising the risk of adverse events.

---

Significant Drug Interactions

Mechanism/Category	Examples of Interacting Medicines	Implication
Metabolic Pathway Inhibition	Moderate CYP3A4 (e.g., Erythromycin), Strong CYP2D6 (e.g., Paroxetine)	Requires caution; may significantly increase tamsulosin concentration.
Pharmacodynamic Potentiation	PDE-5 Inhibitors (e.g., Sildenafil, Tadalafil)	Increased risk of symptomatic hypotension (low blood pressure).

---

Other Constraints

The absorption characteristics of Duodart necessitate that it be taken approximately 30 minutes after the same meal each day. Furthermore, men taking any dutasteride-containing product, including Duodart, must not donate blood until at least six months after their final dose to prevent the potential contamination of blood components with the drug.

Duodart utilizes two distinct, concurrent pharmacological mechanisms to modulate biological factors in the lower urinary tract: enzyme inhibition and receptor antagonism.

Enzyme Inhibition and Prostate Structural Remodeling

The Dutasteride component functions as a potent, irreversible inhibitor of the 5-alpha reductase (5-AR) enzyme (Types I and II). This inhibition prevents the conversion of Testosterone into the more potent androgen, Dihydrotestosterone (DHT). The resulting suppression of intraprostatic DHT limits the hormonal growth stimulus, initiating a molecular cascade that leads to increased cellular apoptosis and a structural reduction in prostatic volume over time.

Alpha-Receptor Antagonism and Functional Muscle Relaxation

The Tamsulosin component is a selective antagonist (blocker) of Alpha-1 left(alpha1 ight) Adrenoceptors, primarily the alpha1A subtype found in the prostate and bladder neck smooth muscle. By blocking these receptors, the drug disrupts the sympathetic nervous system signaling that mediates muscle contraction. This results in the rapid functional relaxation of the muscular tissue, causing a decrease in dynamic resistance within the urethra.

Dual-Target Synergy

The combination utilizes concurrent action against the static component (prostatic tissue mass) via enzyme inhibition and the dynamic component (muscle tone) via receptor antagonism. This dual mechanistic approach generates a physiological effect profile that integrates the immediate functional consequence of muscle relaxation with the delayed consequence of structural volume reduction.

The administration of Duodart follows a standardized, once-daily oral regimen. The recommended dose for adult males is one hard capsule, which is a fixed-dose combination containing 0.5 mg Dutasteride and 0.4 mg Tamsulosin Hydrochloride.

---

Official Dosing and Administration

The capsule must be taken once daily, and timing is crucial: it should be consumed approximately 30 minutes after the same meal each day to ensure consistent absorption of the components. Guidance indicates that the medicine should not be taken on an empty stomach.

Procedurally, the capsule must be swallowed whole with water and must not be chewed, crushed, or opened. This handling requirement is necessary to prevent the contents from irritating the oropharyngeal mucosa and to maintain the integrity of the controlled-release formulation.

Schedule Management and Population Rules

Regarding dose management, if an individual misses a dose, it is generally suggested to take the missed dose as soon as the oversight is noted. However, if it is almost time for the next scheduled dose, the individual should skip the missed dose entirely and resume the regular schedule, and must not double the dose.

This standard, once-daily dosage applies to adult males, including the elderly population. No specific dosage adjustment is anticipated for patients with renal impairment, but caution is advised in patients with mild to moderate hepatic impairment.

Research evidence / Overview of studies for Duodart

Evidence for Symptom Management in BPH

The core research structure for the combination of Dutasteride and Tamsulosin (Duodart) includes large-scale, long-term Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time, comparing the combination against using the two active ingredients individually (monotherapies). The trials included adult men (aged 50 and older) experiencing moderate-to-severe lower urinary tract symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH) who had objective evidence of an enlarged prostate.

Researchers designed the trials to monitor several outcomes related to physical discomfort and functional imbalance, including measurements of symptom severity and Maximum Urinary Flow Rate (Q max). Findings describe patterns observed in the studies where the combination therapy was studied for how symptoms change over time, and the trials reported patterns of change compared to both monotherapy groups. Functional data reported in the studies described measurements of Q max in the combination group that were tracked in relation to the individual monotherapy groups. Research does not determine whether an individual will respond similarly.

Evidence for Managing Clinical Progression

Beyond symptom management, research also examined long-term clinical endpoints. The central outcome studied was a composite measure of serious BPH-related events, tracking the time to the first event of Acute Urinary Retention (AUR) or the need for BPH-related surgery. Data show patterns related to the frequency of composite progression events in the combination group that was associated with a difference when compared to one of the monotherapy groups (Tamsulosin alone) over the four-year duration.

Long-Term Follow-up and Durability of Study Findings

The evidence on the combination therapy includes data derived from trials with a long-term follow-up duration, extending up to four years in major studies. These studies were used in observational settings evaluating daily-life functioning to assess how the observed changes in symptoms and flow rates evolved across the study period. Long-term effects for certain outcomes beyond the four-year study period are not fully established, as research is ongoing.

What Remains Uncertain in the Research Record

One key aspect is that the main four-year study was not structured to compare the combination therapy directly against a placebo for the entire duration. This means that comparative evidence is lacking for the long-term difference versus an inactive treatment from that specific trial. The evidence quality varies across studies and data for certain groups remain insufficient.

Key Studies & References

1. 4-year combination therapy trial (CombAT) in men with benign prostatic hyperplasia: a randomised control study
2. Efficacy and safety of the fixed-dose combination of dutasteride and tamsulosin in the treatment of men with moderate-to-severe lower urinary tract symptoms due to benign prostatic hyperplasia

Common questions about Duodart (FAQ)

---

Q: Does Duodart reduce the risk of acute urinary retention (AUR)?

Regulatory documents indicate that Duodart is intended to reduce the risk of Acute Urinary Retention (AUR) and the need for surgery related to Benign Prostatic Hyperplasia (BPH). This benefit is based on studies of the combination therapy (dutasteride and tamsulosin) used in men with enlarged prostates who are considered at high risk of disease progression.

---

Q: What should I do if I forget to take my Duodart capsule?

Official product information provides guidance for managing a missed dose, which typically involves taking it as soon as it's remembered, unless it is nearly time for the next scheduled dose. The guidance specifies continuing the regimen at the regular time and emphasizes that a double dose should not be taken to compensate for a missed capsule.

---

Q: Can Duodart improve the symptoms of BPH (enlarged prostate)?

Studies and official information indicate that Duodart is approved to treat moderate-to-severe symptoms of Benign Prostatic Hyperplasia (BPH). This combination medicine is designed to relax the muscle in the prostate and cause the prostate to shrink, which can help improve urinary flow and lessen BPH symptoms over time.

---

Q: How long does it take for Duodart to start working to improve symptoms?

According to the official product information, patients may notice an improvement in their symptoms within 2 to 4 weeks after starting treatment with Duodart. However, it is also noted that the full clinical benefit of the medicine may take 6 months or more to be fully observed.

---

Q: Is there a recommended time of day to take Duodart?

Regulatory documents indicate the recommended way to take Duodart is approximately 30 minutes after the same meal each day. This specific timing is mentioned because taking the medicine consistently after a meal helps with the proper absorption of the tamsulosin component.

---

Q: What is the physical appearance of the Duodart capsule?

The Duodart capsule, as described in the official product information, is oblong with a brown body and an opaque orange cap. It is identified by the marking 'GS 7CBL' printed in black ink on the capsule.

---

Storage and Disposal of Duodart (Dutasteride/Tamsulosin)

The Duodart hard capsules must be stored below 25°C in a cool, dry place and be protected from light and moisture. To maintain product stability, the medicine must be kept in its original container until the time of use; storage in damp areas like a bathroom is prohibited. The official requirements mandate that Duodart must be stored out of the sight and reach of children.

Special Handling and Disposal

Due to the dermal absorption risk of Dutasteride, contact with leaking or broken capsules must be avoided. If contact occurs, the skin should be washed immediately with soap and water.

Expired or unused Duodart must be disposed of safely by following local pharmaceutical waste regulations. The medicine should not be disposed of in wastewater or household trash unless specifically permitted by local guidance.